ZYBERNO
Stock Report
Updated Sep 1, 2026

LIPOCINE INC. (LPCN)

Healthcare • NASDAQ

$2.24

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
26.0/100
POOR BUSINESS
LIPOCINE INC. (LPCN) scores 26/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-64.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (-800.8%)
Return on Capital (Capital Efficiency):CRITICAL (-55.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LIPOCINE INC. (LPCN) stock report — Zyberno Score 26/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.24
Market Cap:$18.41M

Valuation Multiples (3)

P/B Ratio:0.85x
P/S Ratio:11.73x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$13.49M

Price Action & Momentum (1)

% of 52-Week High:18.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-57.6%
Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):0.2%

Margin Analysis (3)

Operating Margin Ttm:-800.8%
Net Margin Ttm:-755.1%
Ebitda Margin:-798.0%

TTM Performance (2)

Operating Margin Ttm:-800.8%
Net Margin Ttm:-755.1%

Yield Metrics (2)

Earnings Yield:-$84.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:52.2%
Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):0.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.48x
Quick Ratio:11.48x
Cash Ratio:2.41x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:21,668,820.00
Cash And Cash Equivalents:4,979,430.00
Long Term Debt:$0.00
Net Debt:-$4.91M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.57M
Linear Growth: 53.0%
📊 Click to view full LPCN Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$12.57M

Bottom Line Performance (3)

-$11.85M
Income Before Tax:-$11.85M
Ebitda Ttm:-12,524,634.00

Operating Expenses (5)

Operating Expenses:14,138,012.00
R And D Expense:10,191,362.00
Sga Expense:3,946,650.00
Income Tax Expense:$200.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:5,361.1%
Sga To Revenue Percentage:2,076.1%
Ebitda Margin:-798.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$23.84M
Current Assets:$23.74M
Ppe Net:74,831.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,067,957.00
Current Liabilities:2,067,957.00
Long Term Debt:$0.00
Short Term Debt:$64.45K

Equity & Capital (3)

Equity:$21.77M
Retained Earnings:-$215.69M
Common Stock:75,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:680,525.00

Special Items (2)

Contract Liabilities:320,000.00
Stock Based Compensation:58,145.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.05M-$9.85M

Investment Activities (1)

Investing Cash Flow:-$9.90M

Financing Activities (3)

Financing Cash Flow:$11.97M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:11,964,056.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:43,918.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.87
-$1.79
Earnings Per Share Ttm:-$1.44

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.19
Operating Cash Flow Per Share:-$1.19

Book Value & Capital (2)

Book Value Per Share:$2.65
Cash Per Share:0.61

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.08x
Working Capital Turnover Ttm:0.07x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:158.27
Cash Conversion Cycle:-2,156.27
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):0.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):0.5%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-19.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:LPCN
Company Name:LIPOCINE INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:8.22M
Shares Outstanding Basic:8.22M
Shares Outstanding Diluted:8.22M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:23:54 UTC
Data Timestamp:2026-08-21T08:35:04.911533
Scroll to Top